Cardiomyopathy in type 2 diabetes: Update on pathophysiological mechanisms

Herz

Volumn 33, Issue 3, 2008, Pages 184-190

  Saunders, Justin ^a   Mathewkutty, Shiny ^a   Drazner, Mark H ^a,b   McGuire, Darren K ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diabetes; Free fatty acids; Heart failure; Hyperglycemia; Lipotoxicity; PPAR

Indexed keywords

FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

CARDIOMYOPATHY; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW;

BLOOD GLUCOSE; CARDIOMYOPATHIES; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; PPAR ALPHA; RISK FACTORS;

EID: 42549103818     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-008-3115-3     Document Type: Review

References (72)

1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.
2. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879-84.
3. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:951-7.
4. Pfister R, Erdmann E. Diabetes mellitus und Herzinsuffizienz: Epidemiologie und Therapie. Herz 2008;33:178-83.
5. Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005;294:334-41.
6. Taegtmeyer H, McNulty P, Young ME. Adaptation and mal-adaptation of the heart in diabetes. Part I: General concepts. Circulation 2002;105:1727-33.
7. Young ME, McNulty P, Taegtmeyer H. Adaptation and mal-adaptation of the heart in diabetes. Part II: Potential mechanisms. Circulation 2002;105:1861-70.
8. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovas Dis 1972;15:289-29.
9. Rodrigues B, Cam M, McNeill J. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 1995;27:169-79.
10. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006;291:H1489-506.
11. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy: clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008;51:93-102.
12. Taegtmeyer H, Passmore JM. Defective energy metabolism of the heart in diabetes. Lancet 1985;1:139-41.
13. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle, its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;281:785-9.
14. Ruderman NB, Saha AK, Vavvas D, et al. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol Endocrinol Metab 1999;276:E1-18.
15. Campbell FM, Kozak R, Wagner A, et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002;277:4098-103.
16. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 2000;10:238-45.
17. Finck BN, Lehman JJ, Leone TC, et al. The cardiac phenotype induced by PPAR{alpha} overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121-30.
18. Reddy MK, Hollenberg PF, Reddy JK. Partial purification and immunoreactivity of an 80000-molecular-weight polypeptide associated with peroxisome proliferation in rat liver. Biochem J 1980;188:731-40.
19. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
20. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 1998;273:23786-92.
21. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-36.
22. Ricquier D, Bouillaud F. The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP. Biochem J 2000;345:161-79.
23. Finck BN, Han X, Courtois M, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003;100:1226-31.
24. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A 1999;96:7473-8.
25. Young ME, Patil S, Ying JUN, et al. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor {alpha} in the adult rodent heart. FASEB J 2001;15:833-45.
26. Zhou Y-T, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. PNAS 2000;97:1784-9.
27. Buchanan J, Mazumder PK, Hu P, et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005;146:5341-9.
28. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997;34:25-33.
29. Schmitz-Peiffer C, Craig DL, Biden TJ. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 1999;274:24202-10.
30. Schmitz-Peiffer C. Signalling aspects of insulin resistance in skeletal muscle: mechanisms induced by lipid oversupply. Cell Signal 2000;12:583-94.
31. Thompson AL, Cooney GJ. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes 2000;49:1761-5.
32. Huang B, Wu P, Popov KM, et al. Starvation and diabetes reduce the amount of pyruvate dehydrogenase phosphatase in rat heart and kidney. Diabetes 2003;52:1371-6.
33. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004;109:2191-6.
34. How O-J, Aasum E, Severson DL, et al. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006;55:466-73.
35. Hamilton JA. Fatty acid transport: difficult or easy? J Lipid Res 1998;39:467-81.
36. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
37. Zhou YT, Shimabukuro M, Lee Y, et al. Enhanced de novo lipogenesis in the leptin-unresponsive pancreatic islets of prediabetic Zucker diabetic fatty rats: role in the pathogenesis of lipotoxic diabetes. Diabetes 1998;47:1904-8.
38. Son N-H, Park T-S, Yamashita H, et al. Cardiomyocyte expression of PPAR{gamma} leads to cardiac dysfunction in mice. J Clin Invest 2007;117:2791-801.
39. Yang R, Barouch LA. Leptin signaling and obesity: cardiovascular consequences. Circ Res 2007;101:545-59.
40. Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 1997;94:4637-41.
41. McGarry JD. Glucose-fatty acid interactions in health and disease. Am J Clin Nutr 1998;67:Suppl:500S-4S.
42. McGarry JD. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992;258:766-70.
43. Daniel S, Kim K-H. Sp1 mediates glucose activation of the acetyl-CoA carboxylase promoter. J Biol Chem 1996;271:1385-92.
44. Saha AK, Kurowski TG, Ruderman NB. A malonyl-CoA fuel-sensing mechanism in muscle: effects of insulin, glucose, and denervation. Am J Physiol Endocrinol Metab 1995;269:E283-9.
45. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab 2006;290:E1-8.
46. Eckel RH, Wassef M, Chait A, et al. Prevention Conference VI: Diabetes and cardiovascular disease: Writing Group II: Pathogenesis of atherosclerosis in diabetes. Circulation 2002;105:e138-43.
47. Kent M, Light N, Bailey A. Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro. Biochem J 1985;225:745-52.
48. Petrova R, Yamamoto Y, Muraki K, et al. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 2002;34:1425-31.
49. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-34.
50. Arai M. Advanced glycation endproducts and their receptor: do they play a role in diabetic cardiomyopathy? J Mol Cell Cardiol 2002;34:1305-8.
51. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998;76:725-46.
52. Rajabi M, Kassiotis C, Razeghi P, et al. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 2007;12:331-43.
53. Depre C, Young ME, Ying J, et al. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 2000;32:985-96.
54. 2+-ATPase and phospholamban mRNA expression in response to pressure overload and thyroid hormone. Proc Natl Acad Sci U S A 1989;86:2966-70.
55. Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem 1998;273:29530-9.
56. Allard MF, Schonekess BO, Henning SL, et al. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol Heart Circ Physiol 1994;267:H742-50.
57. Makinde AO, Kantor PF, Lopaschuk GD. Maturation of fatty acid and carbohydrate metabolism in the newborn heart. Mol Cell Biochem 1998;188:49-56.
58. Kagaya Y, Kanno Y, Takeyama D, et al. Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats. A quantitative autoradiographic study. Circulation 1990;81:1353-61.
59. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor [alpha] (PPAR[alpha]) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 2002;34:1249-57.
60. Young ME, Laws FA, Goodwin GW, et al. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 2001;276:44390-5.
61. Paternostro G, Clarke K, Heath J, et al. Decreased GLUT-4 mRNA content and insulin-sensitive deoxyglucose uptake show insulin resistance in the hypertensive rat heart. Cardiovasc Res 1995;30:205-11.
62. Taegtmeyer H, King LM, Jones BE. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol 1998;82:54K-60K.
63. Morgan HE, Henderson MJ, Regen DM, et al. Regulation of glucose uptake in muscle. I. The effects of insulin and anoxia on glucose transport and phosphorylation in the isolated, perfused heart of normal rats. J Biol Chem 1961;236:253-61.
64. Young LH, Renfu Y, Russell R, et al. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 1997;95:415-22.
65. Bolukoglu H, Goodwin GW, Guthrie PH, et al. Metabolic fate of glucose in reversible low-flow ischemia of the isolated working rat heart. Am J Physiol Heart Circ Physiol 1996;270:H817-26.
66. Sun D, Nguyen N, DeGrado TR, et al. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes. Circulation 1994;89:793-8.
67. Dutka DP, Pitt M, Pagano D, et al. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol 2006;48:2225-31.
68. Panagia M, Gibbons GF, Radda GK, et al. PPAR-{alpha} activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 2005;288:H2677-83.
69. Long SD, Pekala PH. Regulation of GLUT4 gene expression by arachidonic acid. J Biol Chem 1996;271:1138-44.
70. Lopaschuk GD, Wall SR, Olley PM, et al. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988;63:1036-43.
71. Sambandam N, Morabito D, Wagg C, et al. Chronic activation of PPAR{alpha} is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 2006;290:H87-95.
72. Yue T-I, Bao W, Jucker BM, et al. Activation of peroxisome proliferator-activated receptor-{alpha} protects the heart from ischemia/reperfusion injury. Circulation 2003;108:2393-9.